Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Doxorubicin Hydrochloride liposomal in Triple Negative Breast Cancer: NCT05949021 Clinical Landscape Report 2026
16 October 2026
NCT05949021 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Diffuse Large B-Cell Lymphoma: NCT05950802 Clinical Landscape Report 2026
16 October 2026
NCT05950802 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Ovarian Cancer: NCT05949424 Clinical Landscape Report 2026
16 October 2026
NCT05949424 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Follicular Lymphoma: NCT05950165 Clinical Landscape Report 2026
16 October 2026
NCT05950165 clinical landscape for Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bendamustine Hydrochloride in B-Cell Lymphoma: NCT05950334 Clinical Landscape Report 2026
16 October 2026
NCT05950334 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fam-trastuzumab deruxtecan-NXKI in Triple Negative Breast Cancer: NCT05953168 Clinical Landscape Report 2026
16 October 2026
NCT05953168 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Everolimus in Metastatic breast cancer: NCT05954442 Clinical Landscape Report 2026
16 October 2026
NCT05954442 clinical landscape for Metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Acalabrutinib in Diffuse Large B-Cell Lymphoma: NCT05952024 Clinical Landscape Report 2026
16 October 2026
NCT05952024 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cetuximab in Glioblastoma Multiforme: NCT05956821 Clinical Landscape Report 2026
16 October 2026
NCT05956821 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NPX267 in Recurrent Triple-Negative Breast Carcinoma: NCT05958199 Clinical Landscape Report 2026
16 October 2026
NCT05958199 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Toripalimab in Ovarian Cancer: NCT05955105 Clinical Landscape Report 2026
16 October 2026
NCT05955105 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Polatuzumab Vedotin-Piiq in Diffuse large B-cell lymphoma refractory: NCT05966233 Clinical Landscape Report 2026
16 October 2026
NCT05966233 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…